D-缬氨酰-L-白氨酰-L-赖氨酸对硝基苯胺二盐酸盐 | 62354-43-2

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 赖氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: D-缬氨酰-L-白氨酰-L-赖氨酸对硝基苯胺二盐酸盐
• 中文别名: D-缬氨酰-L-亮氨酰-L-赖氨酰-对-硝基苯胺二盐酸盐；D-缬氨酰-L-亮氨酰-L-赖氨酸-对-硝基苯胺二盐酸盐
• 英文名称: (S)-6-Amino-2-((S)-2-((R)-2-amino-3-methylbutanamido)-4-methylpentanamido)-N-(4-nitrophenyl)hexanamide dihydrochloride
• 英文别名: (2S)-6-amino-2-[[(2S)-2-[[(2R)-2-amino-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-N-(4-nitrophenyl)hexanamide;dihydrochloride
• CAS: 62354-43-2
• 化学式: C23H40Cl2N6O5
• 分子量: 551.5
• InChiKey: VESQMNNSPPEOSZ-ZLARAOTRSA-N

物化性质

• 溶解度：
  可溶于水

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  36
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  185
• 氢给体数：
  7
• 氢受体数：
  7

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36
• 危险类别码：
  R20/21/22,R36/37/38,R63

文献信息

• Echogenic Vehicle for Clinical Delivery of Plasminogen Activator and Other Fibrin-Binding Therapeutics to Thrombi
  申请人：Laing Susan T.

  公开号：US20080305156A1

  公开（公告）日：2008-12-11

  We disclose a composition comprising an echogenic liposome (ELIP) having an exterior surface, an interior surface, and at least one bilayer comprising at least one lipid selected from the group consisting of saturated phospholipids, unsaturated phospholipids, mixed phospholipids, and cholesterol, and a thrombolytic compound trapped by the ELIP. We also disclose a method of treating a medical condition in a patient characterized by a thrombus in the patient's vasculature, comprising administering to the patient the composition in an amount effective to reduce the size of the thrombus.

  我们披露了一种包含具有外表面、内表面和至少一个由饱和磷脂、不饱和磷脂、混合磷脂和胆固醇中至少一种脂质选择的超声造影脂质体（ELIP）的组合物，并且ELIP困住了一个溶栓化合物。我们还披露了一种治疗患有患者血管系统中血栓的医疗状况的方法，包括向患者投药该组合物，以有效减小血栓的大小。
• Recombinant hybrid immunoglobulin molecules and their use
  申请人：THE GENERAL HOSPITAL CORPORATION

  公开号：EP0355068A2

  公开（公告）日：1990-02-21

  A recombinant hybrid immunoglobulin molecule has an antigen binding site specific for fibrin linked to a second protein comprising the active portion of a plasminogen activator, single-chain urokinase. Cloning and production of these novel hybrid immunoglobulin molecules are also disclosed. The recombinant hybrid immunoglobulin molecules can be used in immuno­diagnostic and immunotherapeutic processes.

  一种重组杂交免疫球蛋白分子具有一个纤维蛋白特异性抗原结合位点，该位点与第二种蛋白质相连，第二种蛋白质包括纤溶酶原激活剂的活性部分，即单链尿激酶。还公开了这些新型杂交免疫球蛋白分子的克隆和生产。重组混合免疫球蛋白分子可用于免疫诊断和免疫治疗过程。
• Pharmaceuticals in joint-linker configurations for treating pathological blood clots
  申请人：Immunwork Inc.

  公开号：US10383947B2

  公开（公告）日：2019-08-20

  The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

  本公开提供了具有靶向元件和效应元件的各种分子构建体。还公开了使用此类分子构建体治疗各种疾病的方法。
• Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi
  申请人：Board of Regents, The University of Texas System

  公开号：US10357448B2

  公开（公告）日：2019-07-23

  We disclose a composition comprising an echogenic liposome (ELIP) having an exterior surface, an interior surface, and at least one bilayer comprising at least one lipid selected from the group consisting of saturated phospholipids, unsaturated phospholipids, mixed phospholipids, and cholesterol, and a thrombolytic compound trapped by the ELIP. We also disclose a method of treating a medical condition in a patient characterized by a thrombus in the patient's vasculature, comprising administering to the patient the composition in an amount effective to reduce the size of the thrombus.

  我们公开了一种组合物，该组合物包含一种回声脂质体（ELIP），该脂质体具有一个外表面、一个内表面和至少一个双分子层，该双分子层包含至少一种选自饱和磷脂、不饱和磷脂、混合磷脂和胆固醇组成的组的脂质，以及一种被ELIP截留的溶栓化合物。我们还公开了一种治疗以患者血管中的血栓为特征的患者病症的方法，包括向患者施用有效量的组合物以减小血栓的大小。
• Functionalized nanoparticles and methods of use thereof
  申请人：REGENTS OF THE UNIVERSITY OF MINNESOTA

  公开号：US10967062B2

  公开（公告）日：2021-04-06

  Certain embodiments of the present invention provide functionalized nanoparticles and methods of use thereof. Certain embodiments provide nanoparticles functionalized with streptokinase. Certain embodiments of the present invention provide methods for treating a pathological fibrin associated disorder (e.g., cancer) in an animal.

  本发明的某些实施方案提供了功能化纳米颗粒及其使用方法。某些实施方案提供了用链激酶功能化的纳米颗粒。本发明的某些实施方案提供了治疗动物病理性纤维蛋白相关疾病（如癌症）的方法。